Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study

November 1, 2025The Lancet OncologyOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To compare the effectiveness of NELSON and PLCOm2012 lung cancer screening eligibility criteria in Germany.
Prospective cohort study conducted in Germany
Included various participants subject to different screening criteria
Evaluated eligibility rates and screening outcomes
Identified differences in screening eligibility between NELSON and PLCOm2012 criteria
Provided insights into the effectiveness of each eligibility criterion
Revealed implications for lung cancer screening practices in Germany

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Prospective cohort study evaluates lung cancer screening eligibility criteria in Germany, indicating differences in effectiveness.

Federal Ministry of Education and Research (German Center for Lung Research) and AstraZeneca.

No takes yet. Share an insight, caveat, or question.

Vogel-Claussen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share